CPPD is an arthropathy with high prevalence among the elderly and a multitude of clinical manifestations that can easily bring to misdiagnosis and therapeutic errors. The possibility to assess different aspects of the disease with only one tool can be of great help for clinicians.

Ultrasound (US) can help to address both the diagnosis and the inflammatory assessment of the disease. In the last years a lot of research has been carried out regarding the applications of US in CPPD. The special OMERACT US sub-task force that is working in CPPD has produced new definitions for identification of CPPD by US and has tested their reliability demonstrating that US can be used reliably at the knees and wrists for assessing CPPD[1,2]. Further, US has been tested also for assessment of inflammatory and structural changes in osteoarthritis demonstrating to be reliable also for this purpose[3].

During the lecture the potential of US in diagnosis and follow-up of patients with CPPD will be presented. Further, a deeper insight into possible pathogenetic mechanisms, based on observations made at US imaging, will be discussed.

REFERENCES:

[1] Filippou G., Scirè C.A., Damjanov N., et al. Definition and reliability assessment of elementary ultrasonographic findings in calcium pyrophosphate deposition disease: A study by the OMERACT calcium pyrophosphate deposition disease ultrasound subtask force. J Rheumatol 2017;44:1744–9. doi:10.3899/jrheum.161057

[2] Filippou G, Scirè CA, Adinolfi A, et al. Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints—an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force. Ann Rheum Dis 2018;:annrheumdis-2017-212542. doi:10.1136/annrheumdis-2017-212542

[3] Bruyn GA, Naredo E, Damjanov N, et al. An OMERACT reliability exercise of inflammatory and structural abnormalities in patients with knee osteoarthritis using ultrasound assessment. Ann Rheum Dis Published Online First: 22 April 2015. doi:10.1136/annrheumdis-2014-206774

Disclosure of Interests: Georgios Filippou Speakers bureau: Laborest, Abbvie, BMS, Sanofi

DOI: 10.1136/annrheumdis-2019-eular.8480